原发性开角型青光眼患者的微脉冲环形光凝疗法:早期结果

V. N. Germanova, A. V. Sorokin, A. Zolotarev, E. Karlova, V. M. Malov, M. V. Radaykina, O. V. Zhukova
{"title":"原发性开角型青光眼患者的微脉冲环形光凝疗法:早期结果","authors":"V. N. Germanova, A. V. Sorokin, A. Zolotarev, E. Karlova, V. M. Malov, M. V. Radaykina, O. V. Zhukova","doi":"10.55531/2072-2354.2023.23.4.27-31","DOIUrl":null,"url":null,"abstract":"Aim – to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) procedure in patients with primary open-angle glaucoma (POAG). \nMaterial and methods. The study was conducted in 21 patients with POAG and uncompensated intraocular pressure (IOP) using pharmacotherapy. All patients underwent MP-TSCPC procedure with IRIDEX Cyclo G6 device. The follow-up period lasted for 1 month. During this time, the visual acuity, IOP dynamics, complications, as well as the number of hypotensive drugs used were evaluated. Statistical analysis was performed using STATISTICA 12.0 software. \nResults. Among patients with moderate and advanced glaucoma, the IOP reduced by 46.7 (3.3; 64.3) % from baseline values by the end of the follow-up period. The target IOP was achieved in 30.7% of patients. In 75% of patients who achieved target IOP, the number of hypotensive drops used was reduced by 1 component. In all patients with terminal stage glaucoma, pain was relieved, and IOP was reduced by 35.5 (8.4; 41.1) %. No intra- or postoperative complications were reported in any case. \nConclusion. MP-TSCPC can be considered as a relatively safe adjunctive method to achieve target IOP in addition to medical treatment in patients with moderate and advanced glaucoma, as well as appropriate method to control pain in patients with the terminal stage of the disease.","PeriodicalId":183034,"journal":{"name":"Aspirantskiy Vestnik Povolzhiya","volume":"1 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Micropulse cyclophoto-coagulation in patients with primary open-angle glaucoma: early results\",\"authors\":\"V. N. Germanova, A. V. Sorokin, A. Zolotarev, E. Karlova, V. M. Malov, M. V. Radaykina, O. V. Zhukova\",\"doi\":\"10.55531/2072-2354.2023.23.4.27-31\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim – to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) procedure in patients with primary open-angle glaucoma (POAG). \\nMaterial and methods. The study was conducted in 21 patients with POAG and uncompensated intraocular pressure (IOP) using pharmacotherapy. All patients underwent MP-TSCPC procedure with IRIDEX Cyclo G6 device. The follow-up period lasted for 1 month. During this time, the visual acuity, IOP dynamics, complications, as well as the number of hypotensive drugs used were evaluated. Statistical analysis was performed using STATISTICA 12.0 software. \\nResults. Among patients with moderate and advanced glaucoma, the IOP reduced by 46.7 (3.3; 64.3) % from baseline values by the end of the follow-up period. The target IOP was achieved in 30.7% of patients. In 75% of patients who achieved target IOP, the number of hypotensive drops used was reduced by 1 component. In all patients with terminal stage glaucoma, pain was relieved, and IOP was reduced by 35.5 (8.4; 41.1) %. No intra- or postoperative complications were reported in any case. \\nConclusion. MP-TSCPC can be considered as a relatively safe adjunctive method to achieve target IOP in addition to medical treatment in patients with moderate and advanced glaucoma, as well as appropriate method to control pain in patients with the terminal stage of the disease.\",\"PeriodicalId\":183034,\"journal\":{\"name\":\"Aspirantskiy Vestnik Povolzhiya\",\"volume\":\"1 6\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-12-09\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Aspirantskiy Vestnik Povolzhiya\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.55531/2072-2354.2023.23.4.27-31\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Aspirantskiy Vestnik Povolzhiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.55531/2072-2354.2023.23.4.27-31","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

目的评价微脉冲经巩膜光凝治疗原发性开角型青光眼(POAG)的疗效和安全性。材料和方法。本研究对21例POAG合并无代偿性眼压(IOP)患者进行了药物治疗。所有患者均采用IRIDEX Cyclo G6装置行MP-TSCPC手术。随访1个月。在此期间,评估患者的视力、眼压动态、并发症以及使用降压药物的数量。采用STATISTICA 12.0软件进行统计分析。结果。在中晚期青光眼患者中,IOP降低46.7 (3.3;64.3) %,从基线值到随访期结束。30.7%的患者达到目标IOP。在75%达到目标IOP的患者中,使用的降压滴剂数量减少了1个组分。在所有终末期青光眼患者中,疼痛得到缓解,IOP降低35.5 (8.4;41.1) %。所有病例均无术中或术后并发症。结论。MP-TSCPC可被认为是中晚期青光眼患者在药物治疗之外实现目标IOP的一种相对安全的辅助方法,也是控制疾病终末期患者疼痛的合适方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Micropulse cyclophoto-coagulation in patients with primary open-angle glaucoma: early results
Aim – to evaluate the efficacy and safety of micropulse transscleral cyclophotocoagulation (MP-TSCPC) procedure in patients with primary open-angle glaucoma (POAG). Material and methods. The study was conducted in 21 patients with POAG and uncompensated intraocular pressure (IOP) using pharmacotherapy. All patients underwent MP-TSCPC procedure with IRIDEX Cyclo G6 device. The follow-up period lasted for 1 month. During this time, the visual acuity, IOP dynamics, complications, as well as the number of hypotensive drugs used were evaluated. Statistical analysis was performed using STATISTICA 12.0 software. Results. Among patients with moderate and advanced glaucoma, the IOP reduced by 46.7 (3.3; 64.3) % from baseline values by the end of the follow-up period. The target IOP was achieved in 30.7% of patients. In 75% of patients who achieved target IOP, the number of hypotensive drops used was reduced by 1 component. In all patients with terminal stage glaucoma, pain was relieved, and IOP was reduced by 35.5 (8.4; 41.1) %. No intra- or postoperative complications were reported in any case. Conclusion. MP-TSCPC can be considered as a relatively safe adjunctive method to achieve target IOP in addition to medical treatment in patients with moderate and advanced glaucoma, as well as appropriate method to control pain in patients with the terminal stage of the disease.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信